Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-04-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于注销部分已授予但尚未行权的股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the cancellation of certain stock options that were granted but not exercised under the company's 2022 stock option incentive plan. It details board and supervisory meetings approving the cancellation, references to legal opinions, and the impact on the company. The document is a formal announcement of a corporate action related to stock options, not a full financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather discloses a corporate governance event related to equity incentives. This fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-15 Chinese
关于公司2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's 2024 annual fundraising funds deposit and usage situation, including amounts raised, usage by year, current balances, management systems, and compliance with regulatory requirements. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes an auditor's and sponsor's verification report on the fundraising funds usage. The document is lengthy (9158 characters) and contains substantive financial data and analysis about the fundraising capital usage, not just an announcement or certification. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. It is not an Annual Report (10-K) or Interim Report (IR) as it focuses specifically on fundraising capital usage, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains detailed data and is not merely announcing a report. Therefore, the correct classification is CAP with high confidence.
2025-04-15 Chinese
2024年度独立董事述职报告（包满珠）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of the company. It details the director's duties, attendance at meetings, independence, communication with auditors, oversight of internal controls, and other governance-related activities. It does not contain financial statements or detailed financial performance data. Instead, it is a report on the independent director's activities and governance oversight for the year. This type of document fits best under Board/Management Information (MANG), as it relates to management and board-level reporting on governance and director duties rather than a financial report or audit report.
2025-04-15 Chinese
关于提前归还部分暂时用于补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Tianyu Biological Technology Co., Ltd. regarding the early repayment of part of idle raised funds temporarily used to supplement working capital. It details the board's approval, the amount repaid, and references previous announcements. The content focuses on capital management and fund usage rather than financial results or reports. The document length is short (723 characters) and it is an announcement about capital usage and repayment, fitting the category of Capital/Financing Update (CAP).
2025-04-08 Chinese
2025年3月养殖业务主要经营数据公告
Regulatory Filings Classification · 95% confidence The document is a monthly operating data announcement for March 2025 from Tianyu Biological Technology Co., Ltd. It provides sales volume, sales revenue, and inventory data for the month and cumulative period, with a disclaimer that the data is unaudited and for investor reference only. The document is short (964 characters) and focuses on operational metrics rather than comprehensive financial statements or detailed analysis. It is not an annual or interim report, nor an earnings release with key highlights. It is a periodic business data update, which fits best under a regulatory announcement category rather than a full financial report. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-04-08 Chinese
关于重新签订猪场租赁合同的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the re-signing of a pig farm lease contract by the company Tianyu Bio-Technology Co., Ltd. It details the transaction overview, parties involved, contract terms, and the impact on the company. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The document is a formal announcement of a business transaction (lease contract) and does not fit into financial reports, earnings releases, or management reports. It is not a regulatory filing in the sense of compliance or officer certification but a specific transaction announcement. The closest fitting category is 'Capital/Financing Update (CAP)' as it relates to a significant lease contract affecting the company's assets and operations, which is a form of capital arrangement. The document length is short (2145 characters), and it is not an announcement of a report publication. Therefore, the best classification is CAP with high confidence.
2025-03-31 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.